Contact SalesSupport Center
Most quality teams don’t suddenly decide that their eQMS needs to be replaced. This is an important decision that is arrived at gradually, through a string of small user frustrations and a lack of features that pile up, resulting in the cost of staying outweighing the cost of moving. Some teams catch the signals early and plan a controlled transition and others wait until an audit finding, a failed scale-up, or a platform sunset notice forces their hand.
Knowing the difference between an eQMS that helps teams succeed and one that’s quietly holding the team back is one of the more important judgments calls a quality leader has to make. The signals worth paying attention to tend to cluster in three areas: how the system is being used day-to-day, how well it keeps up with the company, and what it saves in time, money, and compliance risk.
When workarounds are needed for an eQMS to contribute to the quality system, that eQMS becomes a burden to the quality team. Symptoms of this include manually compiling weekly metrics in Excel due to lackluster dashboards, keeping secondary documents to track document revisions, or using spreadsheets in lieu of notification systems. These quirks might not be immediately obvious in a vendor demo, but they can show up when the client starts using the eQMS for audit prep, new-hire onboarding, or answering an inspector’s question.
The second signal in this category is visibility. If it takes more than a few clicks to confirm overdue training or what version of an SOP is effective, the eQMS isn’t doing what the platform is supposed to do. If the system makes it difficult to answer basic questions during normal operations, the eQMS certainly will not be able to effectively help the team under audit pressure.
Basic eQMS platforms were designed and configured for the company that existed at implementation but might not be sufficient as the company grows larger. New sites, new product lines, and new regulatory markets are where basic systems start to fall short. If adding a new workflow or a new form field requires an entire project plan or a full revalidation cycle, this inflexibility could hamper a growing business; teams running multi-site or distributed operations run into this faster than anyone else.
Another sign here is vendor health; an eQMS platform that hasn’t received a meaningful update in a long time or has fallen behind on validation and support usually means that it has been de-prioritized by its vendor. Support discontinuations and stalled release notes are all signals to start planning a move before the operational timeline becomes too restrictive.
The license fee is only a part of the real cost of a legacy eQMS; annual maintenance, service charges for simple workflow changes, increased validation effort for upgrades, productivity lost to manual workarounds all contribute to unwanted costs.
With updates to quality system requirements across the globe (e.g., FDA QMSR and EU MDR updates, and the EU AI Act), outdated platforms built before these changes might also struggle to support them, and patching old systems to meet new expectations gets expensive quickly. When the system is no longer a useful tool after regulatory updates but a source of additional risk, it’s time to re-evaluate and maybe move on.
The answer to “when should we change our eQMS” is rarely a single event but a pattern of workarounds, visibility gaps, rising costs, and tightening regulations. While one of these issues might not be a strong call to action, when two or three of them are present at the same time, there is now an argument for switching from an eQMS platform.
Teams that run a periodic self-assessment tend to make the transition on their own terms rather than under pressure, and that leads to a planned migration instead of a forced one. If your current eQMS no longer meets your quality and compliance needs, reach out to us to see what ACE can do and how we’ve helped companies big and small achieve success.
Get answers to your questions and discover how ACE can help you elevate your business.
Out-of-specification investigations are one of the most inspected processes in a pharmaceutical lab, and consistently one of the most cited....
The FDA released Draft Guidance Quality Management System Information for Certain Premarket Submission Reviews in October 2025 to prepare medical...
Most quality teams know that manual inspection prep is inefficient, but what’s harder to define is exactly how inefficient it...